US12612369B1 Nicotinonitrile Derivative Patent for Antibacterial and Anti-inflammatory Activities
Summary
The USPTO granted patent US12612369B1 to King Faisal University on April 28, 2026, covering a 4-(4-methoxyphenyl)-6-(1-naphthyl)-2-propoxy-nicotinonitrile compound (MNPN), its eco-friendly synthesis method, and its use as an antimicrobial and anti-inflammatory agent for preventing pressure ulcers in individuals with disabilities. The patent application (No. 19420102) was filed on December 15, 2025, and contains 11 claims under CPC classification C07D 213/85. Inventor Majed Mohammed Ali Alhumaid is listed on the patent.
“A compound 4-(4-methoxyphenyl)-6-(1-naphthyl)-2-propoxy-nicotinonitrile compound, its synthesis, and its use as an antimicrobial and/or anti-inflammatory agent.”
About this source
Granted patents in USPTO classification C07D, covering heterocyclic organic compounds: the chemical core of most small-molecule drugs. Around 160 grants a month. Unlike applications, grants are enforceable. This feed is the best public-domain signal of which small-molecule compositions have just become defensible IP, which matters for generic entry timing, freedom-to-operate opinions, and competitive intelligence. Watch this if you practice pharma IP law, manage a drug discovery patent portfolio, advise on compound licensing, or scout ANDA opportunities as brand drugs approach loss of exclusivity. Recent grants cover apalutamide process improvements and bioactive phenolate ionic complexes.
What changed
The USPTO granted patent US12612369B1 to King Faisal University for a novel nicotinonitrile derivative compound with eco-friendly synthesis and dual antibacterial and anti-inflammatory properties. The patent specifically covers therapeutic applications for preventing pressure ulcers in individuals with disabilities, with 11 claims allowed under CPC classification C07D 213/85.
Pharmaceutical and biotechnology companies developing antimicrobial or anti-inflammatory therapies should review this patent for potential freedom-to-operate considerations, particularly those focused on wound care, pressure ulcer prevention, or disability-related healthcare applications.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Eco-friendly synthesis of a novel nicotinonitrile derivative (MNPN) with antibacterial and anti-inflammatory activities for preventing pressure ulcers in individuals with disabilities
Grant US12612369B1 Kind: B1 Apr 28, 2026
Assignee
KING FAISAL UNIVERSITY
Inventors
Majed Mohammed Ali Alhumaid
Abstract
A compound 4-(4-methoxyphenyl)-6-(1-naphthyl)-2-propoxy-nicotinonitrile compound, its synthesis, and its use as an antimicrobial and/or anti-inflammatory agent.
CPC Classifications
C07D 213/85
Filing Date
2025-12-15
Application No.
19420102
Claims
11
Related changes
Get daily alerts for USPTO Patent Grants - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.